Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090351 | 0.84 | GAA (0.52) | GAARAB9ASMN1; SMN2ALDH1A1NAPRT | |
| SCHEMBL9010775 | 0.83 | RAB9A (0.50) | GAARAB9ASMN1; SMN2ALDH1A1NAPRT | |
| SCHEMBL27683406 | 0.83 | L3MBTL1 (0.55) | GAARAB9ASMN1; SMN2ALDH1A1NAPRT | |
| SCHEMBL5423464 | 0.81 | HDAC1 (0.66) | RAB9ASMN1; SMN2NPC1POLBLMNA | |
| SCHEMBL9821286 | 0.81 | RAB9A (0.48) | GAARAB9ASMN1; SMN2ALDH1A1NAPRT | |
| SCHEMBL103123 | 0.80 | RAB9A (0.61) | GAARAB9ASMN1; SMN2ALDH1A1NAPRT | |
| SCHEMBL27607049 | 0.80 | JUN (0.47) | GAAPOLBLMNAMAPT | |
| SCHEMBL12788711 | 0.79 | EPHX2 (0.47) | POLBLMNAMAPT | |
| SCHEMBL17816224 | 0.79 | LMNA (0.48) | GAARAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL17055207 | 0.79 | HDAC1 (0.64) | SMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160881-B2 | Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide | HOFFMANN-LA ROCHE INC. (US) | 2007-01-09 | — | — | US | claimed |
| US-20040186100-A1 | Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 lambda 6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide | HOFFMANN-LA ROCHE INC. | 2004-09-23 | — | — | US | claimed |
| CN-116947750-A | Preparation method and detection method of netupitant key impurities | 北京民康百草医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-104911650-A | Novel electroplating solution for gallium plating | LIANG SHENGGUANG | 2015-09-16 | — | — | CN | disclosed |
| EP-1654235-B1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-7838540-B2 | 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | SIMITHKLINE BEECHMAN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1592428-B1 | NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N- 6-(1,1-DIOXO-1LAMDA-6 -THIOMORPHOLIN-4-YL)-4(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL -N-METHYL-ISOBUTYRAMIDE | HOFFMANN LA ROCHE (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-7160881-B2 | Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide | HOFFMANN-LA ROCHE INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1654235-A1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1592428-A1 | NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N- 6-(1,1-DIOXO-1&lgr; sp 6 /sp -THIOMORPHOLIN-4-YL)-4(4-F LUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL -N-METHYL-ISOBUTYRAMIDE | F. Hoffmann-La Roche AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| US-6303790-B1 | REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND | HOFFMAN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1103546-A1 | Process for preparation of pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0283762-A1 | Thiazolyl ether and thioether derivatives | BAYER AG (DE) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | MAPK1, MAPK3, MAPKAPK2 | GAA 2213/4885RAB9A 1054/4885SMN1; SMN2 2258/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | GAA 4797/4885RAB9A 2854/4885SMN1; SMN2 3866/4885 |
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | GAA 3670/4885RAB9A 788/4885SMN1; SMN2 2026/4885 |
| US-20040186100-A1 | Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 lambda 6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide | TUBA3C, SFN, CCT4 | GAA 4207/4885RAB9A 3005/4885SMN1; SMN2 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.